LON:SBTX SkinBioTherapeutics (SBTX) Share Price, News & Analysis GBX 10.05 -0.45 (-4.26%) As of 07/7/2026 11:26 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock About SkinBioTherapeutics Stock (LON:SBTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SkinBioTherapeutics alerts:Sign Up Key Stats Today's Range 10▼ 1150-Day Range 6.60▼ 12.1452-Week Range 5▼ 23Volume71,858 shsAverage Volume3.59 million shsMarket Capitalization£26.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom. Read More Receive SBTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SkinBioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SBTX Stock News HeadlinesSkinBioTherapeutics restates FY25 accounts following investigation into former CEO conduct (SBTX)June 8, 2026 | uk.finance.yahoo.comSkinBioTherapeutics Finalises Financial Investigation and Appoints New Auditor Ahead of Results Publication (SBTX)May 28, 2026 | uk.finance.yahoo.com$2 an acre. They paid $412.Government land listed at $2 an acre sold for $412 - 206 times asking price. Demand got so intense the feds doubled auction frequency on geothermal rights in the same Utah desert where a drilling crew hit 2035 targets twelve years early. Google signed a 15-year deal. Gates wrote the check. One company controls the entire chain. August 18th, the next auction hits that exact territory - and the whole industry is watching. | Behind the Markets (Ad)SkinBioTherapeutics shares jump 10% as mystery investor builds 22% stake through company crisisMarch 13, 2026 | uk.finance.yahoo.comAIM Market Roundup: IQE, System1, SkinBioTherapeuticsMarch 3, 2026 | uk.finance.yahoo.comSkinBioTherapeutics warns on profit amid misconduct probe against former CEOFebruary 17, 2026 | msn.comSkinBioTherapeutics forced to reverse royalty income statementFebruary 16, 2026 | uk.finance.yahoo.comSkinBioTherapeutics shares slide after board moves to reverse £770,000 of accrued royaltiesFebruary 16, 2026 | uk.finance.yahoo.comSee More Headlines SBTX Stock Analysis - Frequently Asked Questions How have SBTX shares performed this year? SkinBioTherapeutics' stock was trading at GBX 15.77 at the beginning of 2026. Since then, SBTX stock has decreased by 36.3% and is now trading at GBX 10.05. How were SkinBioTherapeutics' earnings last quarter? SkinBioTherapeutics plc (LON:SBTX) posted its quarterly earnings results on Monday, June, 8th. The company reported ($0.31) earnings per share (EPS) for the quarter. The firm earned $2.17 million during the quarter. SkinBioTherapeutics had a negative trailing twelve-month return on equity of 5.25% and a negative net margin of 8.73%. How do I buy shares of SkinBioTherapeutics? Shares of SBTX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of SkinBioTherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that SkinBioTherapeutics investors own include OptiBiotix Health (OPTI), Ecora Resources (ECOR), Avacta Group (AVCT), Inspired (INSE), Anglo African Oil & Gas (AAOG) and Avino Silver & Gold Mines (ASM). Company Calendar Last Earnings6/08/2026Today7/07/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:SBTX CIKN/A Webwww.skinbiotherapeutics.com Phone+44-161-4682760FaxN/AEmployees11Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£3.71 million Net Margins-8.73% Pretax MarginN/A Return on Equity-5.25% Return on Assets-61.18% Debt Debt-to-Equity Ratio11.77 Current Ratio6.14 Quick Ratio10.01 Sales & Book Value Annual Sales£5.23 million Price / Sales4.98 Cash FlowGBX 1.12 per share Price / Cash Flow9.00 Book ValueGBX 1.68 per share Price / Book5.99Miscellaneous Outstanding Shares259,169,000Free FloatN/AMarket Cap£26.05 million OptionableNot Optionable Beta0.12 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (LON:SBTX) was last updated on 7/8/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: “This Could Be Bigger Than Nvidia”Fox News contributor Louis Navellier recently sat down to reveal details on Elon Musk's little-known AI projec...InvestorPlace | SponsoredRay Dalio: Buy Gold. Get Paid.Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...Investors Alley | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredThey proved it worked in '76. Then buried it.In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...Behind the Markets | SponsoredElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SkinBioTherapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share SkinBioTherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SBTX Stock Alerts